A case series of adenosine deaminase 2 deficient patients emphasizing treatment and genotype-phenotype correlations by unknown
POSTER PRESENTATION Open Access
A case series of adenosine deaminase 2 deficient
patients emphasizing treatment and genotype-
phenotype correlations
ED Batu1, O Karadag2, EZ Taskiran3, U Kalyoncu2, I Aksentijevich4, M Alikasifoglu3, S Ozen1*
From 8th International Congress of Familial Mediterranean Fever and Systemic Autoinflammatory Diseases
Dresden, Germany. 30 September - 3 October 2015
Introduction
Deficiency of adenosine deaminase 2 (DADA2) causes a
vasculopathy with autoinflammatory features associated
with mutations in CECR1. The phenotype of DADA2
varies from only cutaneous lesions to full-blown sys-
temic disease with central nervous system (CNS) invol-
vement and aneurysms in visceral arteries which may
overlap with the spectrum of polyarteritis nodosa (PAN).
Objective
Our aim was to assess the characteristics of our patients
with DADA2.
Patients and methods
This is a descriptive case series of Turkish patients diag-
nosed with DADA2 at Hacettepe University. We per-
formed Sanger sequencing in order to sequence 10 exons
of CECR1.
Results
We report six DADA2 patients with homozygous p.G47R
mutation in CECR1. All were initially diagnosed as PAN
(one cutaneous, others systemic) fulfilling the classifica-
tion criteria for the disease and all but one having necro-
tizing arteritis lesions at skin biopsy and two had arterial
aneurysms. All patients had a childhood onset of disease
(median age 7.2 years). All had skin lesions varying from
livedo racemosa to necrotic ulcers on fingers. There were
recurrent fever and abdominal pain attacks in our
patients. Four had CNS involvement; three in the form of
strokes and one had borderline intelligence. Two patients
had strabismus and one had optic neuritis. Two of the
patients were sibs and these patients had low IgM. There
was autoantibody positivity in two patients. Two patients
had hematological involvement, one in the form of
macrophage activation syndrome and one myelofibrosis.
One of our patients had focal segmental glomerulosclero-
sis while another patient had renal AA type amyloidosis.
All patients were refractory to corticosteroid treatment.
One patient with extensive systemic amyloidosis was
resistant to immunosuppressive and plasma treatments
and died due to necrotizing pneumonia. One had pro-
longed remission on colchicine. Two responded to eta-
nercept (one partially), one to mycophenolate mofetil
(the patient with a previous diagnosis of cutaneous PAN),
and one plasma treatment (temporarily). Literature review
revealed that patients with homozygous p.G47R mutation
have fewer strokes and predominantly PAN-like pheno-
types compared to the patients with other mutations.
Conclusion
DADA2 may be classified as a secondary vasculitis due
to probable cause. Genotype-phenotype correlation may
exist in DADA2 and etanercept may be a promising
treatment; however, longer follow-up and prospective
studies are needed.
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